Investors

We welcome you to Sofwave’s Investor Relations page and would like to thank you for your interest in our company. Through this page you can find comprehensive and detailed information about our company and the performance of Sofwave.

Investors - SofwaveInvestors - Sofwave

Stock Exchange

  • Date
    Feb 7, 2025
  • TASE Number
    1175439
  • Symbol: SOFW
    SOFW : TASE
  • Last

    1,560
  • Change

    -2.38%
  • Volume

    47,323
  • Turnover

    744,876 NIS
  • Open

    1,624
  • High

    1,665
  • Low

    1,560
  • Market Cap

    544,874 NIS Thousands
Last update : Feb 7, 2025, 01:35:58 PM

Company Profile

  • Leading the Way
    Commitment to Innovation

    Leveraging our team’s deep industry expertise, Sofwave Medical is at the forefront of developing cutting-edge aesthetic solutions. Sofwave and Pure Impact are non-invasive treatments that effortlessly lift, tone, and improve skin laxity, all without needles or surgery, with just remarkable results.

  • people powered
    People-Powered Performance

    Sofwave drives exceptional value through a high-performing culture that blends operational excellence with top talent. Our global reach, strategic partnerships, and unwavering focus on execution and efficiency fuel sustainable growth.

  • customer satisfaction
    Customer Satisfaction and Continuous Growth

    Sofwave is committed to exceeding customer expectations and achieving long-term success by offering exceptional patient experiences, building strong relationships with healthcare providers, and fostering a customer-centric culture.

  • Rewarding
    Strategic Partnerships

    By building strong partnerships with industry leaders, healthcare providers, and other key stakeholders, Sofwave accelerates growth and expands its market reach. These collaborations enhance our ability to deliver innovative solutions to patients worldwide.

Load more

Press Releases

  • Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2024 Topline Financial Results

    Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2024 Topline Financial Results
  • Sofwave Medical Reports Third Quarter 2024 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports Third Quarter 2024 Financial Results and Business Highlights
  • Sofwave Names Larry Laber, Aesthetic Energy-Based Device Sales Veteran, to Role of Executive Vice President, North American Sales

    PostCard - Sofwave Names Larry Laber, Aesthetic Energy-Based Device Sales Veteran, to Role of Executive Vice President, North American Sales
  • Sofwave Receives FDA Clearance for Pure ImpactTM in Strengthening and Firming of Arms in the U.S

    PostCard - Sofwave Receives FDA Clearance for Pure ImpactTM in Strengthening and Firming of Arms in the U.S
  • Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights
  • Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights
  • Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
  • Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

    PostCard - Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer
  • Sofwave Medical Receives 510(k) Marketing Clearance For Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology

    PostCard - Sofwave Medical Receives 510(k) Marketing Clearance For Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology
  • Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm

    PostCard - Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm
  • Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights

Presentations

  • Sofwave Medical Reports Third Quarter 2024 Financial Results and Business Highlights

    Sofwave Medical Reports Third Quarter 2024 Financial Results and Business Highlights
  • Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights.

    PostCard - Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights.
  • Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights

    PostCard - Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights
  • Investor Meeting November 2023

    PostCard - Investor Meeting November 2023
  • Investor Meeting August 2023

    PostCard - Investor Meeting August 2023
  • Investor meeting May 2023

    PostCard - Investor meeting May 2023
  • Q4 and Full Year 2022 Earnings Call

    PostCard - Q4 and Full Year 2022 Earnings Call

2016
Sofwave™ founded in Israel
2017
Prototype and human trials in Europe
2018
US multisite clinical trial and FDA submission
2019
1st FDA clearance - for improvement of fine lines and wrinkles
2020
Sofwave marked its official commercial launch in the US in parallel with receiving CE mark approval for treating fine lines and wrinkles.
2021
The 2nd, 3rd, and 4th FDA clearances were granted for lifting the eyebrows, neck, and submental area, respectively.
2022
The 5th FDA clearance, for improving* the appearance of cellulite, coincided with Sofwave receiving its first U.S. patent.
2023
Sofwave celebrated the release of the new Precise™ handpiece, the activation of Sofwave Smart™, its 6th and 7th FDA clearances for treating acne scars and improving upper arm laxity, and its 2nd U.S. patent.
2024
Sofwave marked the commercial launch of the Pure Impact™ Muscle Toning Module, including its 8th and 9th FDA clearances for strengthening and toning the abdomen, buttocks, thighs, and arms.
Waves
Why Sofwave?
Advanced Solutions. Consistent Results. Superior Value Proposition.

Why Sofwave?

  • 01

    Next Generation Technology

  • 02

    Industry Traction with Global KOL’s

  • 03

    Strong Market Dynamics

  • 04

    Superior Treatment Model and ROI

  • 05

    Exceptional Growth in Global Brand Awareness

  • 06

    Proven Track Record

Management

  • Dr. Shimon Eckhouse Chairman & Co-Founder at Sofwave
    Dr. Shimon EckhouseChairman & Co-Founder
  • Louis Scafuri CEO at Sofwave
    Louis ScafuriChief Executive Officer
  • Assaf Korner, CFO at Sofwave
    Assaf KornerChief Financial Officer
  • Genady Nahshon COO & Site Manager at Sofwave
    Genady NahshonCOO & Site Manager
  • Dr Ruthi Amir, Chief Medical Officer at Sofwave
    Dr. Ruthie AmirChief Medical Officer
  • Lina Omari, Chief Digital Officer at Sofwave
    Lina OmariChief Digital Officer
  • Ariel-Sverdlik Co-Founder and CTO at Sofwave
    Ariel SverdlikCo-Founder and CTO
  • James Bartholomeusz Chief Innovation Officer at Sofwave
    James BartholomeuszChief Innovation Officer
  • Miguel Pardos Chief Commercial Officer at Sofwave
    Miguel PardosChief Commercial Officer
Let’s get the conversation started

Fill out the form below and we will be in touch!

    Contact Us